Short-term Changes in Self-rating Depression Scale Scores after Smoking Cessation in Neurotic Patients

Maki Komiyama, Yuka Ozaki, Yusuke Miyazaki, Akihiro Yasoda, Hiromichi Wada, Hajime Yamakage, Noriko Satoh-Asahara, Tatsuya Morimoto, Akira Shimatsu, Yuko Takahashi and Koji Hasegawa

Abstract:
Objective The psychological status is a key factor in smoking continuance. However, details on short-term changes in mild depressive states after smoking cessation (SC) are still unknown. The purpose of the present study was to investigate these short-term changes.

Methods A total of 989 patients who visited our SC Clinic were assessed using the Zung Self-Rating-Depression-Scale (SDS), an official instrument to measure depressive tendencies. The participants were classified into normal and neurotic groups based on their SDS scores during their initial visit; they were assessed again 2, 4, 8, and 12 weeks thereafter.

Results The majority of patients in the neurotic group were women. These patients were also younger, with a higher nicotine dependence, and presented with a lower successful SC rate than the patients in the normal group. A decrease in SDS scores after starting the SC treatment was observed only in the neurotic group, especially during the first two weeks. In patients who continued to smoke, no improvement in depressive tendencies was noted in this period.

Conclusion Depressive tendencies of patients with neurosis improve in the initial stages of the SC treatment (i.e., within two weeks after starting the treatment). This finding fills the mentioned knowledge gap regarding the effects of SC on mild depressive states in the short term.

Key words: smoking cessation, smoking, nicotine dependence, depression

(Intern Med 60: 1175-1181, 2021) (DOI: 10.2169/internalmedicine.4868-20)

Introduction
Smoking is an important risk factor for non-commutable diseases, such as cancer, chronic obstructive pulmonary disease, diabetes mellitus, cerebral infarction, and myocardial infarction. Advising smokers to quit smoking is critical for reducing the risk of these diseases and thus crucial for all physicians involved in internal medicine. However, smokers in a depressive state have difficulty quitting smoking. Furthermore, smoking and depression form a vicious cycle based on close inter-relationships, synergistically raising the risk of non-commutable diseases.

The number of individuals suffering from depression is increasing annually, which is a major social issue (1). There is a clear correlation between smoking and depression. Individuals with depressive tendencies are, in fact, twice as likely to be smokers (often heavy smokers) (2, 3). The majority (85%) of smokers believe that smoking relieves stress (4). However, smokers feel calm simply because the symptoms of their nicotine withdrawal have temporarily abated (5). In fact, prolonged smoking increases the likelihood of developing psychiatric disorders, such as panic disorders, anxiety disorders, and major depression (6, 7). Furthermore, individuals with high depressive tendencies are more likely to start smoking than others (8).
Quitting smoking is known to improve the quality of life and support positive emotions while reducing depression, anxiety, and stress (4, 5, 9). Quitting smoking can also reduce the risk of developing depressive symptoms to the same level found in non-smokers (10). Most of the studies regarding the effects of quitting smoking on depression have examined an improvement over a relatively extended period of several months to several years (4, 5). When mentally unstable patients with depression quit smoking, their depression is known to temporarily worsen soon after quitting, regardless of the type of nicotine replacement used [a nicotine patch or varenicline (11)]. The authors previously found that over half of patients initially visiting the Smoking Cessation Clinic had neurosis (mild depressive state) but no history of a psychiatric disorder (12). How depressive states change soon after the start of smoking cessation (SC) treatment and the detailed course of these changes over time are unclear for patients with neurosis.

Thus, the present study examined the short-term changes in depressive state (in the order of weeks) after patients with neurosis quit smoking while visiting the Smoking Cessation Clinic to receive drug therapy. Our initial hypothesis was that depressive tendencies would temporarily worsen due to nicotine withdrawal soon after SC and then gradually improve over time.
4, 8, and 12 weeks (three months) thereafter while being treated with transdermal nicotine patches or oral varenicline. On repeated visits, continuity in SC was checked, and specific advice regarding the continuation of the cessation treatment was provided by a nurse and a doctor.

At the end of the three-month anti-smoking treatment period, we assessed whether or not SC had been maintained. A patient was judged to have succeeded in quitting smoking when presenting with an expiratory carbon monoxide (CO) concentration of ≤7 parts per million (ppm) and reporting that they had not smoked for more than 1 week since starting the treatment. An attempt to quit smoking was considered unsuccessful when the patient stopped visiting during the treatment period or continued visiting but failed to quit smoking.

Various parameters were evaluated in these patients at the time of their initial consultation and after SC treatment completion (at 12 weeks after the initial consultation). At each visit, a nurse measured the expiratory CO concentration using the EC50 Micro Smokerlyzer (Bedfont Scientific, Kent, UK), which measures the end-tidal CO electrochemically, with a reported precision rate of <2% (13). On the initial consultation, nicotine dependence was assessed using the Fagerström Test for Nicotine Dependence (FTND), a global standard test for assessing physical nicotine dependence (14-16). Scores range from 0 to 10, with higher scores indicating more severe nicotine dependence. The number of cigarettes smoked per day was determined by asking the smoker, “On average, in the past month, how many cigarettes did you smoke per day?” The Brinkman index was calculated as the daily number of cigarettes multiplied by smoking years.

To assess the severity of depressive states, we used the Zung SDS, an official instrument to measure depressive tendencies, in the form of a self-report questionnaire. The SDS has proven to be a useful tool for tracking changes in depression over time in research studies or in the clinical course following treatment (17, 18). In particular, we used the Japanese version, which has also proven to be reliable, as the test-retest correlation was 0.85, the split-half correlation was 0.73, and Cronbach’s alpha was 0.82 (19, 20). During each visit, a member of the study staff reviewed the questionnaires after they had been completed by the patients themselves. If any omissions or mistakes were found, the patients were asked to fill out the questionnaire again (12, 21). A higher score indicated a more severe depressive state.

The classification by SDS score in the present study was performed according to the classification of the Japanese version of the Zung SDS, which presents the SDS score as the raw score rather than the index (19). The mean±standard deviation of the SDS score in Japanese was 35±12 points in the normal control group versus 49±10 points in the neurotic patient group. Therefore, the ranges of the SDS score were 23-47 points in the normal control group and 39-59 points in the neurotic patient group. Based on these ranges identified by Zung, the patients were divided into 2 groups: the normal (score≤38) or neurotic (score=39-59) group.

All statistical analyses were conducted by a professional statistician using the Statistical Package for Social Sciences (SPSS) software program, version 17.0 (SPSS, Chicago, USA). Normality was assessed using the Shapiro-Wilk test. Various data from initial visits to the clinic were compared using Fisher’s exact test, an independent t-test, or a Mann-Whitney U test. The SDS scores of patients with neurosis and those of normal patients were compared. Changes in data were determined before and after quitting smoking. Data with a normal distribution were compared using a paired t-test, and data with a non-normal distribution were compared using Wilcoxon’s signed-rank test. Overall, the changes in SDS scores were compared using a one-way analysis of variance, and changes at different time points were compared using a paired t-test (with Bonferroni’s correction).

**Ethical aspects**

Informed written consent was obtained from all participants, who took part in this study on a voluntary basis. The study data were anonymized by excluding personal identifiers. The Ethical Review Board of the National Hospital Organization, Kyoto Medical Center approved the study protocol.

**Results**

Of the 989 participants in this study, 24 (2.4%) were on an anti-depressant at their initial visit to the Smoking Cessation Clinic, and 81 (8.2%) were on a tranquilizer or sleep aid.

We classified 520 patients (52.6%) into the normal group and 469 patients (47.4%) into the neurotic group. Items assessed during the initial visit were compared for patients with neurosis and those without, and the results of that comparison are shown in Table 1. A significantly greater number of patients with neurosis were women (p=0.009). The neurotic patients were younger (p<0.001), had smoked for less time (in years: p<0.001), and had higher Fagerström Test for Nicotine Dependence (FTND) scores (p=0.008) than those without neurosis at the initial visit.

To investigate changes in SDS scores after successful SC, individuals who continued to smoke 12 weeks after the start of SC treatment and individuals who decided to stop visiting the Smoking Cessation Clinic (222 patients without neurosis, 249 patients with neurosis) were excluded, including only individuals who successfully quit smoking. The rate at which individuals had successfully quit smoking by 12 weeks after the start of SC treatment was 68% (298/520) in the normal group and 55% (220/469) in the neurotic group. Patients in the neurotic group successfully quit smoking at a significantly lower rate than those in the normal group (p<0.001).

If the SDS scores before and after quitting smoking (dur-
Table 1. Patient Data before Smoking Cessation (n=989).

|          | normal group | neurotic group | p value |
|----------|--------------|----------------|---------|
| Female   | 27.5% (143/520) | 35.4% (166/469) | 0.009 a |
| Age      | 60.2±12.0    | 55.7±13.7      | <0.001 b |
| Daily cigarette consumption (n) | 23.7±13.5 | 23.9±10.6 | 0.832 b |
| Duration of smoking (years) | 38.9±11.5 | 35.2±12.7 | <0.001 b |
| FTND score | 6.7±2.3 | 7.0±2.0 | 0.008 b |
| SDS score | 30.6±4.9 | 46.4±5.2 | <0.001 b |
| CO (ppm) | 13.0 [9.0, 21.0] | 15.0 [9.0, 22.0] | 0.078 c |

Data are presented as the mean±standard deviation or median [interquartile range].

p value: a, Fisher’s exact test; b, unpaired t-test; c, Mann-Whitney U test.

FTND score: Fagerström test for nicotine dependence score, SDS test score: self-rating depression scale test score, CO: carbon monoxide

Table 2. Patient Data before and after Successful SC.

|          | Baseline | After three months | p value |
|----------|----------|--------------------|---------|
| Normal group (n=259) | | | |
| SDS score | 30.7±4.7 | 31.3±7.7 | 0.132 a |
| CO       | 13.0 [9.0, 21.0] | 2.0 [1.0, 3.0] | <0.001 b |
| Neurotic group (n=200) | | | |
| SDS score | 46.4±5.2 | 42.4±8.6 | <0.001 a |
| CO       | 14.0 [9.0, 21.0] | 2.0 [1.0, 3.0] | <0.001 b |

Data are presented as the mean±standard deviation or median [interquartile range].

p value: a, paired t-test; b, Wilcoxon signed rank test.

SC: smoking cessation, SDS score: self-rating depression scale score, CO: carbon monoxide

Characteristics of highly depressed smokers

In the current study, about half of the participants were smokers with highly depressive tendencies (i.e., patients
reported that depressed or neurotic smokers typically con-
tent with the results of other previous studies, which have
of nicotine dependence (2, 23). The results of this study are
depressive symptoms is positively correlated with the degree
In addition, other studies have indicated that the severity of
present with more severe depressive tendencies than men do

Changes in depression levels soon after quitting smoking

Numerous studies have found that depression improves
after quitting smoking, but most of those studies have exam-
ined changes over the long term (e.g., several months to
several years after SC) (5, 26). A study reported that depres-
sive symptoms improve one month after quitting smoking in
patients with psychiatric disorders (27). The current study

Table 3. Changes in SDS Scores of Patients with Neurosis Three Months after Suc-

cessfully Quitting Smoking (n=171).

| Data     | p value among group | p value vs. 0M | p value vs. 2wks | p value vs. 1M | p value vs. 2M |
|----------|---------------------|----------------|-----------------|----------------|----------------|
| SDS_0M   | 46.7±5.3            | <0.001         |                 |                |                |
| SDS_2wks | 44.5±7.5            | 0.001          | <0.001          | >0.999         | >0.999         |
| SDS_1M   | 43.7±8.1            | <0.001         | 0.323           | >0.999         |                |
| SDS_2M   | 43.2±8.6            | 0.999          | 0.301           | >0.999         | b              |
| SDS_3M   | 42.6±8.7            | <0.001         | 0.016           | 0.301          | >0.999         |

Data are presented as the mean±standard deviation.
p value: a, one-way analysis of variance; b, a paired t-test (with a Bonferroni correction).
SDS score: self-rating depression scale score, 0M: baseline, 2wks: two weeks, 1M: one month, 2M: two
months, 3M: three months

Table 4. Baseline Data of Neurotic Patients Who Succeeded Smoking Cessation
(n=171) and Those Failed to the Cessation (n=48).

|                   | successful group | failure group | p value |
|-------------------|------------------|---------------|---------|
| Female            | 33.3% (57/171)   | 41.7% (20/48) | 0.308 a |
| Age               | 56.4±14.1        | 56.8±12.2     | <0.884 b|
| Daily cigarette consumption (no) | 23.1±10.6        | 27.6±12.4     | 0.033   |
| Duration of smoking (years) | 35.3±12.6        | 37.3±11.6     | 0.331 b |
| FTND score        | 6.6±2.1          | 7.5±1.9       | 0.014 b |
| SDS score         | 46.7±5.3         | 45.1±4.6      | 0.067 b |
| CO (ppm)          | 14.0 [9.0, 21.0] | 17.5 [11.0, 31.0] | 0.004 c |

Data are presented as the mean±standard deviation or median [interquartile range].
p value: a, Fisher’s exact test; b, unpaired t-test; c, Mann-Whitney U test.
FTND score: Fagerström test for nicotine dependence score, SDS test score: self-rating depression
scale test score, CO: carbon monoxide

with neurosis). This finding is consistent with the results of
a previous study by the authors, which found that a mild de-
pressive state was ubiquitous among patients visiting the
Smoking Cessation Clinic (12). In the present study, the ma-
jority of patients with neurosis were women, and they had
higher nicotine dependence (FTND score) than patients
without neurosis. A study has reported that women typically
present with more severe depressive tendencies than men do
and have a depression rate twice that found in men (22, 23).
In addition, other studies have indicated that the severity
of depressive symptoms is positively correlated with the degree
of nicotine dependence (2, 23). The results of this study are
consistent with those findings. Our findings are also consistent
with the results of other previous studies, which have reported
that depressed or neurotic smokers typically con-
tinue to smoke (21, 24, 25).

Depressive states improved after SC

After quitting smoking, depression, anxiety, and stress
typically improve over the long term (5, 21). A study has re-
ported that quitting smoking results in greater improvement
in individuals with psychiatric disorders than in those with-
out (5). Furthermore, the extent to which it improves depres-
sion is comparable to or greater than the extent to which
drug therapy (i.e., an antidepressant) alleviates a mood or
anxiety disorder (5). Nevertheless, a study has reported that
trying to quit smoking when one is mentally unstable results
in a worsening (albeit temporary) of one’s mental state in
the short term. In contrast, it was not known how depressive
states change after patients with mild depressive tendencies
quit smoking. In the present study, no significant improve-
ment in depressive states was noted in patients without neu-
rosis 12 weeks after the start of the SC treatment. In con-
trast, a significant improvement was noted in patients with
neurosis. Mentally unstable patients (SDS score of ≥60
points) were excluded from this study, and 98% of the par-
ticipants were not on an anti-depressant. Thus, we believe
this study is the first to find that quitting smoking improves
depressive tendencies in patients with neurosis.
examined the course of depressive states in patients with neurosis in the first few weeks of a SC treatment, while they continued to visit the Smoking Cessation Clinic to receive drug therapy. The results suggest that depressive states in patients with neurosis may improve in the initial stages of quitting smoking (i.e., just two weeks after the start of the SC treatment). Depressive states continued to gradually improve afterwards, but the highest improvement rate was observed in the first two weeks.

No significant improvement was noted in the SDS scores of patients with neurosis who continued to smoke two weeks after the start of the SC treatment. This suggests that the success or failure of SC treatment for highly depressed smokers might be predictable based on whether or not depressive tendencies improve two weeks after quitting smoking. Smokers whose depressive tendencies did not improve soon after SC treatment began might need additional intervention, such as psychiatric support.

The results of this study have demonstrated that the depressive tendency improves in the initial stages after quitting smoking (i.e., just two weeks after the start of SC treatment). This finding contradicts our initial hypothesis that depressive tendencies should temporarily worsen, due to nicotine withdrawal, soon after SC and then gradually improve over time.

Limitations

This study was a single center trial in Japan and showed that two weeks of SC significantly reduced SDS scores in neurotic patients. Whether this reduction serves as a predictor of successful SC or occurs as a result of SC for two weeks is currently unclear. The cause-effect relationship should be clarified by further studies. Typically, half of smokers who continue to smoke decide to stop visiting the Smoking Cessation Clinic. The current study was unable to obtain data on changes in the SDS scores of smokers once they decided to stop visiting the Smoking Cessation Clinic. In other words, whether or not depressive tendencies may temporarily worsen during SC treatment could not be determined for patients who decided to stop visiting the Smoking Cessation Clinic. The severity of depressive tendencies is strongly associated with smoking continuance, so most of these patients are likely to continue smoking. Nevertheless, the possibility that patients who decide to stop visiting the clinic due to temporary worsening of depressive tendencies may successfully quit smoking cannot be ruled out. Thus, whether individuals who decide to stop visiting the clinic are able or unable to quit smoking and changes in depressive states after quitting smoking are topics that need to be studied further in the future.

Conclusion

In patients with neurosis who benefited from SC treatment, an improvement in the depressive status was noted as soon as two weeks after the beginning of SC treatment. The depression levels continued to gradually improve over time, but the highest extent of improvement was observed in the first two weeks. In patients who did not benefit from the SC treatment or who decided to stop visiting the Smoking Cessation Clinic after four weeks, an improvement in depressive tendencies was not noted two weeks after beginning the SC treatment. Thus, the ability or inability of patients with neurosis to quit smoking might be predictable based on whether or not their depressive tendencies improve two weeks after the start of SC treatment.

The authors state that they have no Conflict of Interest (COI).

Financial Support

This work was supported in part by a Grant-in-Aid for Clinical Research from the National Hospital Organization and by a Grant-in-Aid for Scientific Research (19K20139) from the Japan Society for the Promotion of Science.

Acknowledgement

We thank Yuko Iida and Sachiko Terashima for their technical assistance.

References

1. WHO fact sheets “Depression” [Internet]. [updated 2020 Jan 30; cited 2020 Jan 30]. Available from: https://www.who.int/news-room/fact-sheets/detail/depression
2. Pratt LA, Brody DJ. Depression and smoking in the U.S. household population aged 20 and over, 2005-2008. NCHS Data Brief No. 34: 1-8, 2010.
3. Douglas Z, Brian H, Jean CB, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res 10: 1691-1715, 2008.
4. Hajek P, Taylor T, McRobbie H. The effect of stopping smoking on perceived stress levels. Addiction 105: 1466-1471, 2010.
5. Taylor G, McNeill A, Girling A, et al. Change in mental health after SC: systematic review and meta-analysis. BMJ 348: g1151, 2014.
6. Breslau N. Psychiatric comorbidity of smoking and nicotine dependence. Behav Genet 25: 95-101, 1995.
7. Isonese B, Wittchen HU, Stein MB, et al. Smoking increases the risk of panic: findings from a prospective community study. Arch Gen Psychiatry 60: 692-700, 2003.
8. Naomi B. Are baseline depressive symptoms associated with smoking initiation in adolescents? West J Med 170: 265, 1999.
9. Mino Y, Shigemi J, Otsu T, et al. Does SC improve mental health? Psychiatry Clin Neurosci 54: 169-172, 2000.
10. Nakata A, Takahashi M, Ikeda T, et al. Active and passive smoking and depression among Japanese workers. Prev Med 46: 451-456, 2008.
11. Smith RC, Amiaz R, Si TM, et al. Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia: a double-blind randomized trial. PLoS One 11: e0143490, 2016.
12. Hasegawa K, Terashima S, Satoh N, et al. Depressive state of patients on their initial visit to a SC clinic. Smoking Control Science 2: 23-26, 2008 (in Japanese).
13. Hald J, Overgaard J, Grau C. Evaluation of objective measures of smoking status—a prospective clinical study in a group of head and neck cancer patients treated with radiotherapy. Acta Oncol 42: 154-159, 2003.
14. Fagerström KO, Heatherton TF, Kozlowski LT. Nicotine addiction and its assessment. Ear Nose Throat J 69: 763-765, 1990.
15. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict 86: 1119-1127, 1991.
16. Terry A, Rustin MD. Assessing nicotine dependence. Am Fam Physician 62: 579-584, 2000.
17. Zung WW. A SELF-RATING DEPRESSION SCALE. Arch Gen Psychiatry 12: 63-70, 1965.
18. Zung WW, Richards CB, Short MJ. Self-rating depression scale in an outpatient clinic. Further validation of the SDS. Arch Gen Psychiatry 13: 508-515, 1965.
19. Fukuda K, Kobayashi S. A manual of Japanese version of the Zung SDS (Self-rating Depression Scale)-the augmented edition-. Sankyobo, Kyoto, 2011: 6 (in Japanese).
20. Kurimoto A, Awata S, Ohkubo T, et al. Reliability and validity of the Japanese version of the abbreviated Lubben Social Network Scale. Nihon Ronen Igakkai Zasshi (Jpn J Geriat) 48: 149-157, 2011 (in Japanese, Abstract in English).
21. Wada H, Hasegawa K, Terashima S, et al. Self-rating depression scale score is a strong independent predictor of SC outcomes. Smoking Control Science 2: 4-8, 2008 (in Japanese).
22. Keita GP. Psychosocial and cultural contributions to depression in women: considerations for women midlife and beyond. J Manag Care Pharm 13: S12-S15, 2007.
23. Shimada S, Hasegawa K, Wada H, et al. High blood viscosity is closely associated with cigarette smoking and markedly reduced by SC. Circ J 75: 185-189, 2011.
24. Hanssens L, Lustygier V, Anseau M, et al. The motivational week: a new approach in SC. Rev Mal Respir 34: 188-193, 2017.
25. Reid HH, Ledgerwood DM. Depressive symptoms affect changes in nicotine withdrawal and smoking urges throughout SC treatment: preliminary results. Addict Res Theory 24: 48-53, 2016.
26. Zhou ZM, Xu XH, Liang J, et al. The impact of cigarette cessation intervention on mental state of patients with coronary heart disease. Zhonghua Nei Ke Za Zhi (Chin J Intern Med) 55: 854-858, 2016 (in Chinese, Abstract in English).
27. Rodríguez-Cano R, López-Durán A, del-Río EF, et al. Smoking cessation and depressive symptoms at 1-, 3-, 6-, and 12-months follow-up. J Affect Disord 191: 94-99, 2016.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).